الصفحة الرئيسية>>Signaling Pathways>> Others>>Eliglustat (hemitartrate)

Eliglustat (hemitartrate) (Synonyms: Genz-112638)

رقم الكتالوجGC43595

Eliglustat (hemitartrate) هو مثبط سينثيز جلوكوسيريبروسايد محدد وفعال وفعال عن طريق الفم مع IC50 من 24 نانومتر.

Products are for research use only. Not for human use. We do not sell to patients.

Eliglustat (hemitartrate) التركيب الكيميائي

Cas No.: 928659-70-5

الحجم السعر المخزون الكميّة
1mg
21٫00
متوفر
5mg
95٫00
متوفر
10mg
140٫00
متوفر
25mg
366٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Eliglustat is a potent and selective inhibitor of glucosylceramide synthase with an IC50 value of 40 nM for the reduction of glucosylceramide synthesis in K562 cells. Inhibition of glucosylceramide synthase, the rate-limiting enzyme in glycosphingolipid synthesis, also reduces production of cell surface gangliosides GM1 and GM3 on K562 and B16/F10 cells, with IC50 values of 24 and 29 nM, respectively. Eliglustat is specific to glucosylceramide synthase over similar enzymes, having minimal activity (IC50 = >10 μM) at α-glucosidase I and II, lysosomal glucocerebrosidase (GBA1), non-lysosomal glucosylceramidase (GBA2), sucrase, and maltase. In vivo, eliglustat induces a dose-dependent decrease in glucosylceramide accumulation in the liver and lungs of D409V/null mice, a model of Gaucher disease. It also prevents further glucosylceramide accumulation if administered after liver and lung deposits have been established.

مراجعات

Review for Eliglustat (hemitartrate)

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eliglustat (hemitartrate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.